Carl H. June, M.D., professor of pathology and laboratory medicine at the Perelman School of Medicine and director of translational research, Abramson Cancer Center at the University of Pennsylvania is the principal investigator on the pancreas cancer trial.
University of Pennsylvania’s Abramson Cancer Center and the Perelman School of Medicine reported that 27 out of 29 patients with an advanced blood cancer saw their cancers go into remission or disappear altogether when they received genetically modified T-cells that were equipped with synthetic molecules called chimeric antigen receptors, or CARs. Those T-cells were able to target and destroy the tumor cells – specifically the ones that were responsible for the acutelymphoblastic leukemia the patients were suffering from.
According to officials at the Fred Hutchinson Cancer Research Center, See more at.
Dr. Carl June Offers Pancreatic Cancer Patients Revolutionary New Immunotherapy Trials on Osteosarcoma. Dr. Pan Pantziarka New research suggests that using the drug ketorolac just before surgery may reduce the rate of metastatic disease and so save lives.